awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q35834336-1A6EF637-32E7-4B8F-B43F-F95D1150C69A
Q35834336-1A6EF637-32E7-4B8F-B43F-F95D1150C69A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35834336-1A6EF637-32E7-4B8F-B43F-F95D1150C69A
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.
P2860
Q35834336-1A6EF637-32E7-4B8F-B43F-F95D1150C69A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35834336-1A6EF637-32E7-4B8F-B43F-F95D1150C69A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7e7068fcc142d82f28e7811d7fbf0e0407ff6c6f
P2860
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).